Compare BBAR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | ICUI |
|---|---|---|
| Founded | 1886 | 1984 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | BBAR | ICUI |
|---|---|---|
| Price | $18.39 | $151.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 793.3K | 245.2K |
| Earning Date | 03-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | $1,535,146,865.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $0.64 | N/A |
| Revenue Next Year | $15.77 | N/A |
| P/E Ratio | $29.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.76 | $107.00 |
| 52 Week High | $23.10 | $165.17 |
| Indicator | BBAR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 52.99 |
| Support Level | $17.04 | $148.71 |
| Resistance Level | $20.82 | $154.79 |
| Average True Range (ATR) | 1.12 | 4.65 |
| MACD | -0.26 | -0.31 |
| Stochastic Oscillator | 31.68 | 37.28 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.